中国药物警戒 ›› 2022, Vol. 19 ›› Issue (4): 395-399.
DOI: 10.19803/j.1672-8629.2022.04.11

• 基础与临床研究 • 上一篇    下一篇

黄芪-防风药对治疗新型冠状病毒肺炎的网络药理学研究

吴作敏1, 杨娟1, 王隆隆1, 王瑞1,2,3,*   

  1. 1漯河市中心医院药学部,河南 漯河 462000;
    2河南省中药制剂现代化技术研发与临床应用工程研究中心,河南 漯河 462000;
    3漯河市药物制剂与药理学重点实验室,河南 漯河 462000
  • 收稿日期:2020-12-26 出版日期:2022-04-15 发布日期:2022-04-15
  • 通讯作者: *王瑞,男,硕士,主任药师,中药学。E-mail:wangrui56116@163.com
  • 作者简介:吴作敏,女,硕士,主管药师,中药制剂与药理学。
  • 基金资助:
    河南省中央引导地方科技发展专项(漯财预指[2020]309号、漯科[2020]7号); 河南省工程研究中心(豫发改高技[2019]569号)

Network Pharmacology of Astragalus-Rhizoma Saposhnikovia divaricata drug pair in the treatment of COVID-19

WU Zuomin1, YANG Juan1, WANG Longlong1, WANG Rui1,2,3,*   

  1. 1Department of Pharmacy, Luohe Central Hospital, Luohe Henan 462000, China;
    2Henan Engineering Research Center of TCM Preparation Modernization Technology and Clinical Application, Luohe Henan 462000, China;
    3Luohe Key Laboratory of Pharmaceutical Preparations and Pharmacology, Luohe Henan 462000, China
  • Received:2020-12-26 Online:2022-04-15 Published:2022-04-15

摘要: 目的 探讨黄芪-防风药对治疗新型冠状病毒肺炎的药理机制。方法 通过中药系统药理学分析平台(TCMSP)检索黄芪、防风的有效化学成分和相关靶点;采用Cytoscape软件绘制成分靶点可视化网络,并进行拓扑分析;在GeneCards数据库挖掘新型冠状病毒肺炎的相关靶点,利用Venny平台筛选黄芪-防风药对治疗新型冠状病毒肺炎的核心靶点,借助STRING数据库构建核心靶点蛋白互作网络,并对核心靶点基因进行基因本体(Gene Ontology, GO)功能富集和京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genomes, KEGG)通路富集分析。结果 共筛选出黄芪、防风主要活性成分36个,主要有槲皮素、山柰酚、汉黄芩素等,其对应靶点215个,其中59个核心靶点如血管内皮生长因子A(VEGFA)、白细胞介素6(IL-6)、肿瘤坏死因子(TNF)、抑癌基因TP53(TP53)、丝裂原激活蛋白激酶8(MAPK8)等涉及GO条目286个(P<0.05),KEGG信号通路97条(P<0.05)。主要涉及癌症信号通路、低氧诱导因子(HIF-1)信号通路及Toll样信号通路等。结论 黄芪-防风药对可通过多组分、多靶点、多通路治疗新型冠状病毒肺炎。

关键词: 黄芪, 防风, 新型冠状病毒肺炎, 网络药理学

Abstract: Objective To investigate the pharmacological mechanism of Astragalus-Rhizoma Saposhnikovia divaricata against Covid-19. Methods The effective components and related target protein of Astragalus-Rhizoma and Saposhnikovia divaricata were screened via the Traditional Chinese Medicine Systems Pharmacology (TCMSP) analysis platform. An effective compound- target protein visual network was established using Cytoscape software, and topology analysis was performed. The targets related to COVID-19 were found via the GeneCards online analysis platform. The core targets were selected by the Venny platform, and a protein-protein interaction (PPI) network of the core targets was constructed and analyzed by STRING database. GO (Gene Ontology) enrichment and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment of target protein coding genes were performed using DAVID database. Results A total of thirty-six types of effective compounds which included quercetin, kaempferol and wogonin, 215 targets and 59 core targets which included VEGFA, IL-6, TNF, TP53 and MAPK8 were selected. GO functional enrichment analysis obtained 286 GO items (P<0.05), while KEGG pathway enrichment analysis obtained 97 pathways related to COVID-19 P<0.05), involving cancer signaling pathways, HIF-1 and Toll like signaling pathways. Conclusion The active compounds in Astragalus-Rhizoma Saposhnikovia divaricata drug pair can exert a preventive or therapeutic effect on COVID-19 by means of multiple components, multiple targets and multiple pathways.

Key words: Astragalus-Rhizoma, Saposhnikovia divaricata, novel coronavirus pneumonia, network pharmacology

中图分类号: